Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
PRTA Description — Prothena Corp Plc

Prothena is a clinical stage biotechnology company focused on the discovery and development of antibodies for the treatment of diseases that involve protein misfolding or cell adhesion. Co.'s research and development pipeline includes: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 for the treatment of Parkinson's disease; and PRX003 for the treatment of inflammatory disease and metastatic cancers. Co.'s pipeline also includes other late discovery stage programs for which Co. is testing antibodies in preclinical models of disease and generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.

Company Name:  Prothena Corp Plc
Website:  www.prothena.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PRTA:  21
Total Market Value Held by ETFs:  $105,056,377
Total Market Capitalization:  $1,604,000,000
% of Market Cap. Held by ETFs:  6.55%
 ETF   PRTA Weight   PRTA Amount 
 XBI   1.08%   $28,056,436         
 IWM   0.08%   $27,565,150         
 IBB   0.25%   $20,974,261         
 CSD   1.84%   $9,781,911         
 IWN   0.13%   $8,043,625         
 IWC   0.39%   $3,715,140         
 IWO   0.04%   $3,141,039         
 VXF   0.04%   $1,609,204         
 BIB   0.14%   $1,262,778         
 IWV   0.01%   $414,173         
List of all 21 ETFs holding PRTA »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Thu, Jun 25, 8:30 AM, Zacks
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
These five stocks have contributed much to the outstanding performance of this biotech ETF.

Wed, Jun 10, 1:35 PM, Zacks
Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog
Prothena Corporation plc (PRTA) dosed the first patient in a phase I study on PRX003 for the potential treatment of psoriasis and other inflammatory diseases.

ETFs Holding PRTA | Prothena Corp Plc | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2015, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.